Suraksha Diagnostic Limited — Updates, 08-02-2025: Press Release

Suraksha Diagnostic Limited reported notable financial performance for the quarter and nine months ended December 31, 2024. Total income for nine months reached INR 1,900.3 million, reflecting a 14.4% increase year-on-year. EBITDA grew by 22.4% to INR 650.8 million, with a margin expansion of 229 bps to 34.8%. For Q3, total income was INR 601.1 million, up 14.1% year-on-year, but down 11.7% sequentially.

The company's profit after tax (PAT) for the nine-month period surged 41.7% to INR 238.1 million, and in Q3 it stood at INR 59.9 million, marking a 31.9% increase year-on-year. These strong results underline Suraksha’s operational efficiency and strategic execution, despite challenges from external factors like a doctors’ strike. The management expressed confidence in pursuing growth through new centers and potential acquisitions, positioning the company for positive long-term revenue and margin growth. Investors should watch closely as the company focuses on strengthening its market presence in the Eastern region of India.